10-K · March 26, 2026
Cognition Therapeutics is a clinical-stage biotech focused on developing zervimesine (CT1812), an oral small molecule for Alzheimer’s disease and dementia with Lewy bodies (DLB). The company has advanced multiple Phase…
Earnings analysis · 10-Q
CGTX earnings analysis
Filed May 8, 2026 · Our reading of the company's report
The latest report
Cognition Therapeutics reported Q4 2026 financial results with a narrower loss compared to the previous year, despite no revenue generation. The net loss for the quarter was $4.6 million, improving from $8.5 million in…
Read full summary
Cognition Therapeutics reported Q4 2026 financial results with a narrower loss compared to the previous year, despite no revenue generation. The net loss for the quarter was $4.6 million, improving from $8.5 million in Q4 2025, showing operational efficiencies. Management highlighted ongoing clinical trials and an upcoming FDA meeting as pivotal for future growth.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.01
What stood out
-
Reduced Net Loss Compared to Last Year
The net loss for Q4 2026 was $4.6 million, significantly down from $8.5 million in Q4 2025.
-
Improved EPS
The diluted EPS improved from -$0.14 in Q4 2025 to -$0.05 in Q4 2026.
-
Operating Expenses Decrease
Total operating expenses in Q4 2026 were $8.8 million, down from $13.8 million in Q4 2025.
-
Cash Reserves Maintained
Cognition Therapeutics had $31.2 million in cash, cash equivalents, and restricted cash as of March 31, 2026.
-
Grant Income Supports Research
Received $4.0 million in grant income in Q4 2026, although this was down from $5.1 million in Q4 2025.
-
Upcoming FDA Meeting
Management anticipates a meeting with the FDA in May 2026 to discuss regulatory plans for zervimesine.
What to watch
-
Ongoing Net Losses
Despite improvements, the company continues to post net losses, with a reported loss of $4.6 million in Q4 2026.
-
Reliance on Grant Funding
Continued reliance on grants, which may not be assured or forthcoming, impacting long-term sustainability.
-
FDA Regulatory Risks
Future success hinges on FDA approval processes, especially for new trials related to zervimesine.
Management's outlook
No specific numeric guidance provided; outlook discussed in broader context.
Earlier filings 4
10-Q · November 6, 2025
Cognition Therapeutics reported a materially smaller GAAP net loss in Q3 2025 of $4,930 (EPS -$0.06) versus a loss of $9,937 (EPS -$0.25) in Q3 2024. Operating expenses fell sharply to $6,375 from $14,463…
10-K · March 26, 2024
Cognition Therapeutics (CGTX) is a clinical-stage biotech developing CT1812, an oral S2R modulator, currently in multiple Phase 2 programs (SHINE enrolled 158; SHIMMER 120; MAGNIFY up to 246; START planned 540). The…
10-Q · August 8, 2023
Cognition Therapeutics reported improved operating and bottom-line results in Q2: net loss narrowed to $4,726,000 (EPS -$0.16) versus a loss of $5,752,000 (EPS -$0.25) in Q2 2022. Operating expenses declined modestly to…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.